-
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
Strengthening GeoVax’s Team Advancing Gedeptin® Clinical Program Atlanta, GA, January 8, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and…
-
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated Atlanta, GA, January 4, 2024 – GeoVax Labs,…
-
GeoVax Announces Issuance of Malaria Vaccine Patent
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment Atlanta, GA, January 3, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company…